Midyear 2022: Life sciences deals return to pre-pandemic levels
Our Biopharma and Medtech Deals and Venture Outlook offers a midyear look at upfront cash, IPOs, potential acquisitions and other trends.
Following years of record-breaking activity, biopharma and medtech dealmaking continued to see declines across its subsectors in the second quarter of 2022.
J.P. Morgan’s Biopharma and Medtech Deals and Venture Outlook report examines the sector at midyear to provide insights on industry trends we might see for the remainder of 2022. The report, powered by DealForma, highlights:
- Biopharma and medtech venture: Both decreased from 2021’s peak, but are still near the top of the 2017 to mid-2020 range.
- Advanced therapies and manufacturing: Contract development and manufacturing remained the most active subsector in medtech, with greater shifts to cell and gene therapy programs in biopharma.
What does this mean for the rest of 2022?
- PIPEs and later-stage rounds will likely see an uptick in activity as private funds deploy investments.
- Clinical outcomes must impress across multiple programs to attract funding and meet patient needs.
Read the full report to get all the insights.